LAGUNA HILLS, Calif.–(BUSINESS WIRE)–Sonendo, Inc. (“Sonendo”), a leading dental technology company and developer of the GentleWave® System, today reported financial results for the quarter ended March 31, 2022.
Recent Highlights
“We are very proud of our quarterly results and start to the year, as we continue to see strong utilization among our install base, despite the spike in Omicron infection rates early in the quarter,” said Bjarne Bergheim, Chief Executive Offer of Sonendo. “Additionally, we recently showcased our new CleanFlow procedure instrument at the American Association of Endodontists conference in Phoenix having just announced the start of our full market release. Simpler for doctors and better for patients, our CleanFlow procedure instrument provides an opportunity for us to improve utilization while also positively changing the margin profile of our business. Lastly, on April sixth we amended our credit agreement with Perceptive Credit Holdings which provided Sonendo an additional $20 million of available credit. This amendment enhances our liquidity position, giving us the optionality needed to further support the growth of our business.”
First Quarter 2022 Financial Results
Total Revenue was $9.0 million in the first quarter 2022, an increase from $7.4 million in the first quarter 2021. Growth in the quarter was primarily driven by increased GentleWave console sales and procedure instruments sales. GentleWave console revenue was $2.1 million in the first quarter 2022, an increase from $1.8 million in the first quarter 2021. Procedure instrument revenue was $4.3 million, an increase from $3.3 million in the first quarter 2021. Software revenue was $1.8 million, an increase from $1.6 million in the first quarter 2021.
As of March 31, 2022, GentleWave ending install base was approximately 850 units.
Gross margin for first quarter 2022 was 25%, compared to 23% in the first quarter 2021. The increase in gross margin was driven primarily by higher average selling price and improved overhead absorption, partially offset by increased costs relating to supply chain disruptions in the first quarter 2022.
Total operating expenses in the first quarter 2022 were $16.8 million, compared to $11.6 million in the first quarter 2021. The increase was driven primarily by higher personnel related expenses, sales hiring, marketing and higher general and administrative costs, primarily legal and accounting associated with operating as a public company.
Loss from operations was $14.6 million in the first quarter 2022, compared to $9.8 million in the first quarter 2021. Non-GAAP loss from operations was $12.8 million in the first quarter 2022 compared to $8.8 million in the first quarter 2021. Non-GAAP loss from operations excludes revaluation of contingent consideration, stock-based compensation expense, and depreciation and amortization expense.
Net loss was $15.5 million for the first quarter 2022, compared to $10.9 million in the first quarter 2021.
Cash and cash equivalents as of March 31, 2022 totaled $66.1 million, while long-term borrowings totaled $30.0 million.
2022 Financial Guidance
The Company expects full year 2022 total revenue to be in the range of $40 million to $43 million, consistent with guidance previously provided.
Webcast and Conference Call Information
Sonendo will host a conference call to discuss the first quarter 2022 financial results after the market close on Tuesday, May 10th, 2022 at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by dialing (844) 200-6205 for domestic callers or (929) 526-1599 for international callers, using access code: 477282. Live audio of the webcast will be available on the “Investors” section of the company’s website at: https://investor.sonendo.com. The webcast will be archived and available for replay for at least 90 days after the event.
About Sonendo
Sonendo is a commercial-stage medical technology company focused on saving teeth from tooth decay, the most prevalent chronic disease globally. Sonendo develops and manufactures the GentleWave® System, an innovative technology platform designed to treat tooth decay by cleaning and disinfecting the microscopic spaces within teeth without the need to remove tooth structure. The system utilizes a proprietary mechanism of action, which combines procedure fluid optimization, broad-spectrum acoustic energy and advanced fluid dynamics, to debride and disinfect deep regions of the complex root canal system in a less invasive procedure that preserves tooth structure. The clinical benefits of the GentleWave System when compared to conventional methods of root canal therapy include improved clinical outcomes, such as superior cleaning that is independent of root canal complexity and tooth anatomy, high and rapid rates of healing and minimal to no post-operative pain. In addition, the GentleWave System can improve the workflow and economics of dental practices. Sonendo is also the parent company of TDO® Software, the developer of widely used endodontic practice management software solutions, designed to simplify practice workflow. TDO Software integrates practice management, imaging, referral reporting and CBCT imaging, and offers built-in communication with the GentleWave System.
For more information about Sonendo and the GentleWave System, please visit www.sonendo.com. To find a GentleWave doctor in your area, please visit www.gentlewave.com.
Forward Looking Statements
In addition to background and historical information, this press release contains “forward-looking statements” based on Sonendo’s current expectations, forecasts and beliefs including statements related to Sonendo’s 2022 financial guidance. These forward-looking statements are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Actual outcomes and results could differ materially due to a number of factors, including the ongoing uncertainty of the impact of the COVID-19 pandemic, as well as COVID recovery impact, on its business. These and other risks and uncertainties include those described more fully in the company’s Annual Report on Form 10-K for the year ended December 31, 2021 filed with the U.S. Securities and Exchange Commission (SEC) on March 23, 2022 under the sections titled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation”, as well as any reports that we may file with the SEC in the future. Forward-looking statements contained in this announcement are based on information available to Sonendo as of the date hereof. Sonendo undertakes no obligation to update such information except as required under applicable law. These forward-looking statements should not be relied upon as representing Sonendo’s views as of any date subsequent to the date of this press release and should not be relied upon as prediction of future events. In light of the foregoing, investors are urged not to rely on any forward-looking statement in reaching any conclusion or making any investment decision about any securities of Sonendo.
Use of Non-GAAP Financial Measures
Sonendo’s financial results are prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). This press release and the reconciliation tables included in the financial schedules below include non-GAAP loss from operations. Non-GAAP loss from operations exclude, as applicable, (i) revaluation of contingent consideration, (iii) stock-based compensation expense, and (iii) depreciation and amortization. Management believes that non-GAAP loss from operations are useful in helping identify the company’s core operating performance and enables management to consistently analyze the period-to-period financial performance of the core business operations. Management also believes that non-GAAP loss from operations, will enable investors to assess the company in the same way that management has historically assessed the company’s operating results against comparable companies with conventional accounting methodologies. The company’s definitions of non-GAAP loss from operations have limitations as analytical tools and may differ from other companies reporting similarly named measures. Non-GAAP measures should not be considered measures of financial performance under GAAP, and the items excluded from such non-GAAP measures should not be considered in isolation or as alternatives to financial statement data presented in the financial statements as an indicator of financial performance or liquidity. Non-GAAP measures should be considered in addition to results prepared in accordance with GAAP but should not be considered a substitute for or superior to GAAP results.
For a reconciliation of our non-GAAP loss from operations presented herein to GAAP loss from operations, the most directly comparable GAAP financial measures, please see “Reconciliation of GAAP to Non-GAAP Loss from Operations” in the financial schedules below.
|
SONENDO, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands, except share data) |
||||||||
|
|
|
March 31, |
|
|
December 31, |
|
||
|
|
|
2022 |
|
|
2021 |
|
||
|
|
|
(Unaudited) |
|
|
|
|
||
|
ASSETS |
|
|
|
|
|
|
||
|
Current assets: |
|
|
|
|
|
|
||
|
Cash and cash equivalents |
|
$ |
66,054 |
|
|
$ |
84,641 |
|
|
Accounts receivable, net |
|
|
2,702 |
|
|
|
2,516 |
|
|
Inventory |
|
|
10,134 |
|
|
|
8,150 |
|
|
Prepaid expenses and other current assets |
|
|
3,968 |
|
|
|
3,552 |
|
|
Total current assets |
|
|
82,858 |
|
|
|
98,859 |
|
|
Property and equipment, net |
|
|
2,177 |
|
|
|
2,366 |
|
|
Operating lease right-of-use assets |
|
|
2,478 |
|
|
|
2,746 |
|
|
Intangible assets, net |
|
|
2,790 |
|
|
|
2,956 |
|
|
Goodwill |
|
|
8,454 |
|
|
|
8,454 |
|
|
Other assets |
|
|
118 |
|
|
|
118 |
|
|
Total assets |
|
$ |
98,875 |
|
|
$ |
115,499 |
|
|
LIABILITIES AND STOCKHOLDERS’ EQUITY |
|
|
|
|
|
|
||
|
Current liabilities: |
|
|
|
|
|
|
||
|
Accounts payable |
|
$ |
2,235 |
|
|
$ |
3,061 |
|
|
Accrued expenses |
|
|
4,416 |
|
|
|
4,758 |
|
|
Accrued compensation |
|
|
2,513 |
|
|
|
3,376 |
|
|
Operating lease liabilities |
|
|
966 |
|
|
|
975 |
|
|
Other current liabilities |
|
|
1,957 |
|
|
|
2,482 |
|
|
Total current liabilities |
|
|
12,087 |
|
|
|
14,652 |
|
|
Operating lease liabilities, net of current |
|
|
1,474 |
|
|
|
1,730 |
|
|
Term loan, net of current |
|
|
26,620 |
|
|
|
26,496 |
|
|
Other liabilities |
|
|
517 |
|
|
|
558 |
|
|
Total liabilities |
|
|
40,698 |
|
|
|
43,436 |
|
|
Commitments and contingencies (Note 8) |
|
|
|
|
|
|
||
|
Stockholders’ equity: |
|
|
|
|
|
|
||
|
Preferred stock, $0.001 par value; authorized —10,000,000 shares; issued and outstanding – none |
|
|
— |
|
|
|
— |
|
|
Common stock, $0.001 par value; authorized — 500,000,000 shares; issued — 26,465,797 shares as of March 31,2022 and 26,383,225 shares as of December 31, 2021; outstanding — 26,419,108 shares as of March 31, 2022 and 26,336,536 shares as of December 31, 2021 |
|
|
26 |
|
|
|
26 |
|
|
Additional paid-in-capital |
|
|
385,768 |
|
|
|
384,132 |
|
|
Accumulated deficit |
|
|
(327,566 |
) |
|
|
(312,044 |
) |
|
|
|
|
58,228 |
|
|
|
72,114 |
|
|
Less: Treasury stock |
|
|
(51 |
) |
|
|
(51 |
) |
|
Total stockholders’ equity |
|
|
58,177 |
|
|
|
72,063 |
|
|
Total liabilities and stockholders’ equity |
|
$ |
98,875 |
|
|
$ |
115,499 |
|
|
SONENDO, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (unaudited) (In thousands, except share and per share data) |
||||||||
|
|
|
Three Months Ended March 31, |
|
|||||
|
|
|
2022 |
|
|
2021 |
|
||
|
Product revenue |
|
$ |
7,203 |
|
|
$ |
5,809 |
|
|
Software revenue |
|
|
1,830 |
|
|
|
1,618 |
|
|
Total revenue |
|
|
9,033 |
|
|
|
7,427 |
|
|
Cost of sales |
|
|
6,754 |
|
|
|
5,685 |
|
|
Gross profit |
|
|
2,279 |
|
|
|
1,742 |
|
|
Operating expenses: |
|
|
|
|
|
|
||
|
Selling, general and administrative |
|
|
11,985 |
|
|
|
6,524 |
|
|
Research and development |
|
|
4,850 |
|
|
|
5,046 |
|
|
Change in fair value of contingent earnout |
|
|
— |
|
|
|
14 |
|
|
Total operating expenses |
|
|
16,835 |
|
|
|
11,584 |
|
|
Loss from operations |
|
|
(14,556 |
) |
|
|
(9,842 |
) |
|
Other expense, net: |
|
|
|
|
|
|
||
|
Interest and financing costs, net |
|
|
(966 |
) |
|
|
(1,064 |
) |
|
Loss before income tax expense |
|
|
(15,522 |
) |
|
|
(10,906 |
) |
|
Income tax expense |
|
|
— |
|
|
|
— |
|
|
Net loss and comprehensive loss |
|
$ |
(15,522 |
) |
|
$ |
(10,906 |
) |
|
Net loss per share attributable to common stock – basic and diluted |
|
$ |
(0.59 |
) |
|
$ |
(9.05 |
) |
|
Weighted-average shares outstanding – basic and diluted |
|
|
26,405,252 |
|
|
|
1,205,314 |
|
|
SONENDO, INC. RECONCILIATION OF GAAP TO NON-GAAP LOSS FROM OPERATIONS (In thousands) |
||||||||
|
|
|
Three Months Ended March 31 |
|
|||||
|
|
|
2022 |
|
|
2021 |
|
||
|
GAAP loss from operations |
|
$ |
14,556 |
|
|
$ |
9,842 |
|
|
Adjustments: |
|
|
|
|
|
|
||
|
Revaluation of contingent consideration |
|
|
— |
|
|
|
(14 |
) |
|
Stock based compensation: |
|
|
|
|
|
|
||
|
Included in cost of sales |
|
|
(101 |
) |
|
|
(61 |
) |
|
Included in selling, general and administrative |
|
|
(978 |
) |
|
|
(292 |
) |
|
Included in research and development |
|
|
(315 |
) |
|
|
(141 |
) |
|
Depreciation and amortization |
|
|
|
|
|
|
||
|
Included in cost of sales |
|
|
(171 |
) |
|
|
(148 |
) |
|
Included in selling, general and administrative |
|
|
(193 |
) |
|
|
(302 |
) |
|
Included in research and development |
|
|
(48 |
) |
|
|
(87 |
) |
|
Non-GAAP loss from operations |
|
$ |
12,750 |
|
|
$ |
8,797 |
|
Contacts
Investor Contact:
Gilmartin Group
Matt Bacso, CFA
IR@Sonendo.com
Burlington, Ontario--(Newsfile Corp. - July 2, 2024) - Rapid Dose Therapeutics Corp. (CSE: DOSE) ("RDT"…
NEW YORK, July 2, 2024 /PRNewswire/ -- The global load monitoring systems market size is…
ATLANTA, July 2, 2024 /PRNewswire/ -- Aveanna Healthcare ("Aveanna") has learned of a data security…
These 50 rising stars are honored for their trailblazing innovations in shaping global culture UNIONDALE,…
MRO achieves highest client satisfaction ratings for ROI and secure provider data exchange in Black…
LAGUNA NIGUEL, Calif., July 2, 2024 /PRNewswire/ -- Alleva, a premier provider of electronic medical…